Key result
Aspirin cuts recurrent cardiovascular events ~19% after myocardial infarction, despite increased bleeding risk.
Why the study?
Aspirin is widely used for secondary prevention of MI, but its comparative efficacy against newer antiplatelet regimens remains debated.
Does aspirin or alternative antiplatelet therapy reduce recurrent cardiovascular events and mortality in adults with prior myocardial infarction?
Meta-Analysis (n=327,987)
Does aspirin or alternative antiplatelet therapy reduce recurrent cardiovascular events and mortality in adults with prior myocardial infarction?
Aspirin remains foundational for secondary MI prevention, but personalized strategies utilizing 81 mg dosing, P2Y12 monotherapy for high bleeding risk, or time-limited DAPT for high ischemic risk optimize patient outcomes.
Answers are grounded in this paper and cite their sources.
Supports aspirin for secondary MI prevention; confirms efficacy across 14 studies with 19% recurrent event reduction.
Aspirin is widely used for secondary prevention of myocardial infarction (MI), but its comparative efficacy against newer antiplatelet regimens remains debated. This study, therefore, aimed to evaluate aspirin's role in secondary MI prevention by assessing its effectiveness, safety, and potential alternatives. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-compliant meta-analysis, including 14 studies (n = 327,987) published between 2000 and 2024, was conducted. Random-effects models were applied to pool risk ratios (RRs) for cardiovascular events and bleeding outcomes. Subgroup analyses were performed according to dosing, comorbidities, and treatment strategies. Aspirin reduced recurrent events by 19% (RR: 0.81, 95% CI: 0.78-0.84) but increased bleeding risk, particularly at the 325 mg dose. P2Y₁₂ inhibitors demonstrated comparable efficacy with lower bleeding risk (HR: 0.56-0.95). Extended dual antiplatelet therapy (DAPT) benefited high-risk patients, such as those post-percutaneous coronary intervention (PCI) (HR: 0.85, 95% CI: 0.75-0.96) and those with diabetes (HR: 0.86, 95% CI: 0.75-0.99), but was associated with higher bleeding risk (HR: 1.3-1.8). Monotherapy exhibited lower heterogeneity (I² = 46.75%) than dual therapy (I² = 70.31%). Overall, aspirin remains a cornerstone of secondary prevention. Still, personalized strategies-favoring 81 mg dosing, P2Y₁₂ inhibitors in patients at high bleeding risk (HBR), and time-limited DAPT in those at high ischemic risk-appear to optimize outcomes.
No takes yet. Share an insight, caveat, or question.
Maimani et al. (2025) conducted a meta-analysis in Myocardial Infarction (n=327,987). Aspirin vs. Placebo, no treatment, or alternative antiplatelet agents was evaluated on Recurrent cardiovascular events (RR 0.81, 95% CI 0.78-0.84). Aspirin reduced recurrent cardiovascular events by 19% (RR 0.81) in patients with prior myocardial infarction, though it was associated with an increased bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: